Results 201 to 210 of about 15,877,700 (238)

Carbon Markets and Green Innovation: Path‐Dependent Firm Responses to Emissions Trading

Business Strategy and the Environment, EarlyView.
ABSTRACT This paper identifies a dynamic boundary condition of the Porter hypothesis by examining how firms' pre‐existing innovation trajectories shape regulatory‐induced green innovation within the context of a market‐based carbon policy. Building on path dependency theory, we argue that firms' responses to environmental regulation are contingent on ...
Rushi Chen, Effie Kesidou, Peter Howley
wiley   +1 more source

Editorial: Optimizing the therapeutic potential in clinical settings: leveraging placebos and mitigating nocebo effects. [PDF]

Front Psychol
Faria V, Bernstein M, Annoni M, Furmark T, Moulton EA.   +4 more
europepmc   +1 more source

Strategic Silence? Mandatory Sustainability Disclosure and the Discipline of Corporate Over‐Claiming Under the European Union Non‐Financial Reporting Directive

Business Strategy and the Environment, EarlyView.
ABSTRACT This study examines whether mandatory sustainability disclosure under the European Union Non‐Financial Reporting Directive (NFRD) reduces corporate greenwashing among listed European firms, with a focus on the 500‐employee compliance threshold.
Giacomo Zatini, Nicola Torricella, Armando della Porta   +2 more
wiley   +1 more source

Beyond concealment: Translating placebo research into migraine care. [PDF]

Headache
Kleine-Borgmann J, Schmidt K, Bingel U.
europepmc   +1 more source

Disclosure, Verification, and Value: The Impact of Climate Risk Disclosure on Institutional On‐Site Research and Economic Consequences

Business Strategy and the Environment, EarlyView.
ABSTRACT Based on signaling theory and information asymmetry theory, this study uses a sample of Chinese A share listed firms from 2012 to 2023 to examine the effect of climate risk disclosure (CRD) on institutional on‐site research and its economic consequences.
Sha Tang, Chante Jian Ding, Abdullahi D. Ahmed   +2 more
wiley   +1 more source

Viral Dynamic Model‐Informed Dose Selection of Mosnodenvir Prophylaxis against DENV‐3 in a Controlled Human Infection Model

Clinical Pharmacology &Therapeutics, EarlyView.
Dengue virus (DENV) infection is a significant global health threat. Mosnodenvir (JNJ‐64281802) is a pan‐serotype small molecule antiviral blocking DENV replication. A Phase IIa study (NCT05048875) evaluated the antiviral activity, safety, and pharmacokinetics of mosnodenvir as prophylaxis against DENV‐3 in a controlled human infection model (CHIM).
Nele Goeyvaerts, Xavier Woot de Trixhe, Martine Neyens, Thomas N. Kakuda, Liesbeth Van Wesenbeeck, Annemie Buelens, Freya Rasschaert, Anna Durbin, Oliver Ackaert   +8 more
wiley   +1 more source

Triglyceride Polygenic Score Identifies Individuals Who May Respond Differently to Aspirin in Primary Prevention

Clinical Pharmacology &Therapeutics, EarlyView.
Low‐dose aspirin is no longer routinely recommended for the primary prevention of cardiovascular disease in older adults due to a lack of net benefit over bleeding risk. We hypothesized that genetic subgroups may experience differential harm or benefit from aspirin therapy.
Peter D. Fransquet, Chenglong Yu, Cammie Tran, Sultana Monira Hussain, Chad A. Bousman, Mark R. Nelson, Andrew M. Tonkin, John J. McNeil, Paul Lacaze   +8 more
wiley   +1 more source

Mechanisms of open and hidden placebo in stroke recovery: targeting neuroplasticity insights of the placebo effect - study protocol for a controlled, parallel, randomised clinical trial. [PDF]

BMJ Open
Ortega-Márquez J, Camargo L, Gianlorenço AC, Sosa W, Black-Schaffer R, Wang QM, Fregni F.   +6 more
europepmc   +1 more source

Model‐Informed Approaches for Pediatric Type 2 Diabetes Evidence Generation: Insights from a Model‐Based Longitudinal HbA1c Meta‐Analysis from EMA Marketing Authorization Applications

Clinical Pharmacology &Therapeutics, EarlyView.
Evidence generation for antihyperglycemic therapies in pediatric type 2 diabetes mellitus (T2DM) remains challenging, with most randomized trials failing to demonstrate statistically significant reductions in glycated hemoglobin (HbA1c), partly due to substantial between‐subject variability.
Pieter J. Colin, Efthymios Manolis, Jeroen V. Koomen   +2 more
wiley   +1 more source

The Possibility of Open-Label Use of Placebo in Healthcare Practice: A Systematic Review of Recent Clinical Trials. [PDF]

Cureus
Tao FCW, Ghafoor F, Yang N.
europepmc   +1 more source